ComparisonInterventions

Statins vs Ezetimibe

First-line LDL lowering vs an add-on

StatinsHMG-CoA reductase inhibitors

EzetimibeCholesterol-absorption inhibitor

Last reviewed: July 2026
Version: 1.0
Review cadence: Annually

At a Glance

The 30-second view

LDL lowering
Statins
Large (~30–50%+)
Ezetimibe
Modest (~15–20%)
Outcome evidence
Statins
Extensive (event + mortality)
Ezetimibe
Adds benefit on top of statin (IMPROVE-IT)
Typical role
Statins
First-line
Ezetimibe
Add-on when statin alone falls short or isn't tolerated
Cost
Statins
Low (generic)
Ezetimibe
Low (generic)

Dimension	Statins	Ezetimibe
LDL lowering	Large (~30–50%+)	Modest (~15–20%)
Outcome evidence	Extensive (event + mortality)	Adds benefit on top of statin (IMPROVE-IT)
Typical role	First-line	Add-on when statin alone falls short or isn't tolerated
Cost	Low (generic)	Low (generic)

Overview

Both lower LDL cholesterol but by different mechanisms and to different degrees. Statins reduce hepatic cholesterol synthesis; ezetimibe blocks intestinal cholesterol absorption. They are complementary rather than truly competing.

Quick summary

Statins are first-line and lower LDL far more, with the deepest outcome evidence. Ezetimibe lowers LDL modestly and, added to a statin, further reduces events (IMPROVE-IT) — making it a valuable add-on or an option when statins can't be tolerated, not a replacement.

When each is appropriate

Choose Statins

As first-line lipid lowering for essentially everyone who needs it — the larger LDL reduction and outcome evidence.

Choose Ezetimibe

Added to a statin to reach goal, or as an alternative/partial option when a statin is not tolerated.

Evidence comparison

Mechanism
Statins
Blocks cholesterol synthesis
Ezetimibe
Blocks cholesterol absorption
LDL reduction
Statins
~30–50%+ (intensity-dependent)
Ezetimibe
~15–20%
Outcome evidence
Statins
Extensive standalone benefit
Ezetimibe
Adds benefit atop a statin (IMPROVE-IT)
BioSignal evidence maturity
Statins
Established
Ezetimibe
Established (as add-on)

Dimension	Statins	Ezetimibe
Mechanism	Blocks cholesterol synthesis	Blocks cholesterol absorption
LDL reduction	~30–50%+ (intensity-dependent)	~15–20%
Outcome evidence	Extensive standalone benefit	Adds benefit atop a statin (IMPROVE-IT)
BioSignal evidence maturity	Established	Established (as add-on)

Safety comparison

Common issues
Statins
Muscle symptoms (often nocebo); small diabetes signal
Ezetimibe
Generally very well tolerated
Tolerability niche
Statins
—
Ezetimibe
Useful when statins aren't tolerated

Dimension	Statins	Ezetimibe
Common issues	Muscle symptoms (often nocebo); small diabetes signal	Generally very well tolerated
Tolerability niche	—	Useful when statins aren't tolerated

Strengths & limitations

Statins

Largest LDL reduction

Deepest outcome and mortality evidence

First-line, inexpensive

Muscle-symptom concerns (mostly nocebo) in some

Ezetimibe

Very well tolerated

Adds event reduction on top of a statin

Option when statins can't be used

Modest LDL lowering alone

Best evidence is as an add-on, not monotherapy

Frequently asked questions

Is ezetimibe as good as a statin?

Alone, no — it lowers LDL much less and has less outcome evidence. Its real value is added to a statin to reach goal, or as a fallback when statins aren't tolerated.

Continue Exploring

Where to go next

References & sources

IMPROVE-IT trial
2018 ACC/AHA Cholesterol Guideline

Comparisons synthesize BioSignal's existing calibrated evidence — they introduce no new conclusions. Figures and verdicts trace to the linked Signal Records and Foundations.

Educational information — not medical advice

Comparisons orient a decision; they don't make it for you. Choices between medications, supplements, or programs belong with a qualified clinician. See our Medical Disclaimer.

Is this comparison clear, balanced, and useful? Your feedback shapes what we review next.

Give feedback